Definitive Homecare Solutions e-prescribing earns Surescripts certification
COLUMBUS, Ohio — Electronic prescribing network Surescripts has certified Definitive Homecare Solutions’ CPR+ specialty pharmacy software for e-prescribing.
Definitive Homecare Solutions said CPR+ incorporates e-prescribing capabilities into a workflow queue that is designed specifically for specialty pharmacies, helping meet specialty pharmacies’ needs by providing a step-by-step process to guide them through patient intake, medication dispensing and refill, clinical patient assessment and reimbursement.
"We continually look for ways to enable greater efficiencies for our customers through automation," Definitive Homecare Solutions co-owner Stuart Crane said. "With the dramatic increase in the adoption of e-prescribing among physicians practices, the addition of e-prescribing to our offering to the specialty pharmacy market presents a tremendous opportunity for our customers to lower costs and increase referrals by taking advantage of this technology."
Yankee Candle introduces Perfect Pillar
SOUTH DEERFIELD, Mass. — Yankee Candle has introduced its latest candle form.
The Perfect Pillar features an easy-to-remove peel-off label, adding to the overall clean, contemporary look of this decorative candle form, Yankee Candle said.
“We are excited to offer our customers endless decorating possibilities, in fragrances they have come to expect and love from Yankee Candle, with our new Perfect Pillar Candle line,” Yankee Candle SVP brand, design and innovation Hope Margala Klein said. “We look forward to hearing about its success from our customers as they welcome this product into their homes.”
The Perfect Pillar retails for $19.99 per 12-oz. candle and is available at retail, online and in specialty retailers and gift shops.
Impax confirms patent challenge for generic Jalyn
HAYWARD, Calif. — Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.
The generic drug maker said that GlaxoSmithKline filed a patent infringement suit against Impax in the District of Delaware last week in connection with its attempt to market dutasteride and tamsulosin hydrochloride 0.5 mg/0.4 mg capsules, a generic version of Jalyn. The suit was filed after Impax submitted an abbreviated new drug application containing a paragraph IV certification for the drug with the Food and Drug Administration.
Once the ANDA is approved by the FDA, Impax’s generic division intends to commercialize the product.
Jalyn, designed to treat symptomatic BPH in men with an enlarged prostate, garnered U.S. sales of about $41 million for the 12-month period ended in July, according to Wolters Kluwer Health data.